Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients

PURPOSE: AZD1775 is a first-in-class Wee1 inhibitor with dual function as a DNA damage sensitizer and cytotoxic agent. A phase I study of AZD1775 for solid tumors suggested activity against brain tumors, but a preclinical study indicated minimal blood-brain barrier penetration in mice. To resolve th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Sanai, Nader, Li, Jing, Boerner, Julie, Stark, Karri, Wu, Jianmei, Kim, Seongho, Derogatis, Alanna, Mehta, Shwetal, Dhruv, Harshil D., Heilbrun, Lance K., Berens, Michael E., LoRusso, Patricia M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6865048/
https://ncbi.nlm.nih.gov/pubmed/29798906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-3348
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados